Demographic, clinical and laboratory data of patients
| Age/Sex | Disease duration, years | Cutaneous subset | Autoantibodies | Previous immunosupresive treatment | RTX cycles | Follow-up after RTX, months | FVC (predicted%) | |
|---|---|---|---|---|---|---|---|---|
| Before RTX | After RTX | |||||||
| 52/F | 7.0 | Diffuse | ANA, Scl-70 | CYC, MMF | 2 | 12 | 44 | 44 |
| 39/M | 10.1 | Diffuse | ANA, Scl-70 | MMF | 4 | 24 | 75 | 79 |
| 55/F | 5.0 | Diffuse | ANA, Scl-70 | MMF | 4 | 24 | 75 | 70 |
| 43/F | 16.6 | Limited | ANA, Scl-70 | CYC, MMF | 1 | 6 | 38 | 47 |
| 50/F | 4.6 | Limited | ANA, Scl-70 | CYC, MMF | 4 | 24 | 52 | 57 |
| 65/F | 13,0 | Diffuse | ANA, Scl-70 | CYC, MMF | 1 | 6 | 42 | 41 |
| 48/F | 5.7 | Limited | ANA, Scl-70 | CYC | 4 | 24 | 67 | 64 |
| 54/F | 18.9 | Diffuse | ANA, Scl-70 | CYC, MMF | 2 | 12 | 39 | 57 |
| 53/F | 15.0 | Limited | ANA, Scl-70 | CYC, MMF | 5 | 30 | 53 | 44 |
| 56/F | 5,1 | Limited | ANA, Scl-70 | CYC | 1 | 6 | 40 | 45 |
| 52/F | 8.2 | Limited | ANA | – | 3 | 12 | 59 | 59 |
| 18/F | 11.2 | Diffuse | ANA, Scl-70 | MMF | 1 | 6 | 63 | 73 |
| 62/F | 4.6 | Limited | ANA, Scl-70 | CYC, MMF | 3 | 18 | 51 | 61 |
| 54/F | 13.1 | Limited | ANA, Scl-70 | CYC, MMF | 5 | 30 | 54 | 67 |
FVC, forced vital capacity; ANA, antinuclear antibody; Scl-70, antitopoisomerase-1 antibody; CYC, cyclophosphamide; MMF,mycophenolate mofetil; RTX, rituximab.